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Abstract: Reactive oxygen species (ROS) play an important role as endogenous mediators in several 
cellular signalling pathways. However, at high concentrations they can also exert deleterious effects 
by reacting with many macromolecules including DNA, proteins and lipids. The precise balance 
between ROS production and their removal via numerous enzymatic and nonenzymatic molecules 
is of fundamental importance for cell survival. Accordingly, many neurodegenerative disorders, 
including Parkinson’s disease (PD), are associated with excessive levels of ROS, which induce 
oxidative damage. With the aim of coping with the progression of PD, antioxidant compounds are 
currently receiving increasing attention as potential co-adjuvant molecules in the treatment of these 
diseases, and many studies have been performed to evaluate the purported protective effects of 
several antioxidant molecules. In the present review, we present and discuss the relevance of the 
use of Drosophila melanogaster as an animal model with which to evaluate the therapeutic potential 
of natural and synthetic antioxidants. The conservation of most of the PD-related genes between 
humans and D. melanogaster, along with the animal’s rapid life cycle and the versatility of genetic 
tools, makes fruit flies an ideal experimental system for rapid screening of antioxidant-based 
treatments. 
Keywords: antioxidants; Drosophila melanogaster; oxidative damage; Parkinson’s disease; SOD-
mimetics 
 
1. Introduction 
Parkinson’s disease (PD) is a chronic and progressive movement disorder that affects 
approximately 1–2% of the population over the age of 65 years. Clinically, the pathology is mainly 
characterised by resting tremor, rigidity, bradykinesia and postural instability. However, the 
symptomatology of the disease is nowadays considered more complex, also including non-motor 
symptoms such as depression, sleep disturbance and cognitive decline [1]. From a neuropathological 
point of view, PD is characterised by a preferential loss of dopaminergic neurons within the 
substantia nigra pars compacta, and by the deposition of intracellular inclusions, referred to as Lewy 
bodies (LBs), in the surviving neurons [2]. Although the majority of PD cases are idiopathic, the 
identification of genetic forms of the pathology has contributed to partially elucidating the cellular 
mechanisms behind the syndrome. Familial manifestations account for ~10% of the disease and are 
classified into dominant and recessive forms according to the pattern of inheritance [3]. Among the 
causative genes, SNCA and LRRK2 are associated with dominant PD cases, while Parkin, PINK1 and 
DJ-1 contribute to recessive forms of the disease [4]. α-Synuclein is the major component of LBs in 
sporadic PD forms, while LRRK2 is a kinase implicated in different cellular functions, including 
vesicle trafficking, synaptic morphogenesis and neurite outgrowth. Parkin, PINK1 and DJ-1 are all 
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proteins differentially involved in mitochondrial homeostasis. Parkin, an E3 ubiquitin ligase, and 
PINK1, a serine–threonine protein kinase, cooperate to maintain mitochondrial quality control, 
driving the disposal of damaged or old mitochondria, while DJ-1 is a multitasking protein principally 
implicated in the activation of antioxidant responses [4]. Although it is still unclear what triggers PD, 
growing bodies of evidence have suggested that unbalanced redox homeostasis is a common feature 
underlying both sporadic and idiopathic manifestations [5]. As previously discussed, multiple 
sources appear to contribute to the redox alterations observed in the disease, including mitochondrial 
dysfunction, neuroinflammation and dopamine metabolism [5]. Mitochondria have received special 
interest in PD etiopathology, especially considering that numerous PD-related genes and 
neurotoxins, such as MPTP, rotenone and paraquat (PQ), have been shown to affect mitochondrial 
functionality [6]. As mitochondria are considered a primary source of reactive oxygen species (ROS), 
mitochondrial dysfunctions are believed to abundantly participate in driving the state of oxidative 
stress observed in the disease [7]. Similarly, through the chronic activation of microglia, 
neuroinflammation can be responsible for a conspicuous production of ROS, which, if not detoxified, 
contributes to amplification of the state of oxidative stress [8]. Additionally, dopaminergic neurons 
are particularly vulnerable to oxidative damage because the metabolism of dopamine can itself act 
as a further source of ROS in the disease [9]. In light of these considerations, antioxidants are 
currently receiving attention as co-adjuvant molecules in PD treatment, and many studies in this 
frame have been published using different animal models of PD (Figure 1). In the present review, we 
discuss the advantages of Drosophila melanogaster as a model organism by focusing, in particular, on 
PD and its related redox alterations, and emphasising the therapeutic potential of the antioxidant 
drugs.  
 
Figure 1. Beneficial effects of antioxidant treatment on the maintenance of redox homeostasis in 
Parkinson’s disease (PD). PD pathology is associated with an unbalanced redox state, which is the 
result of mitochondrial dysfunction, neuroinflammation and dopamine metabolism. Antioxidant 
therapies can help to hinder excessive oxidative stress conditions by buffering reactive oxygen species 
(ROS) production and limiting ROS-related damage. Antioxidant treatments encompass both natural 
(e.g., vitamins and plant extracts) and synthetic compounds (e.g., superoxide dismutase-mimetics), 
and can promote the stimulation of the endogenous antioxidant defence system. Therefore, the 
antioxidant treatment can act as a co-adjuvant to currently used PD therapies. 
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2. Drosophila melanogaster as a Model Organism in Scientific Research 
The history of Drosophila melanogaster as a model organism in science began a little over 100 
years ago, when Thomas Hunt Morgan and his school demonstrated the theory of chromosomal 
inheritance of Mendelian factors [10]. Over the years, D. melanogaster has become a model in modern 
genetics and is used for the study of several fundamental physiological and behavioural processes, 
most of which are conserved in higher eukaryotes, including mammals. In addition, D. melanogaster 
is considered a valuable model with which to investigate different aspects of human pathologies in 
translational studies. 
Several factors have contributed to make D. melanogaster an informative model. Some are linked 
to the intrinsic characteristics of the organism, such as its short life cycle (about 10 days at 25 °C), 
high fecundity (females lay more than 800 eggs during their lifetime), high number of progeny per 
generation, and the absence of meiotic recombination in males. Furthermore, fruit flies are easy to 
grow and manipulate in the laboratory, and the generation of fly mutant strains has become 
relatively easy (see below). All these aspects have facilitated genetic studies, including those 
requiring the generation of specific fly lines or high numbers of individuals for powerful statistical 
analyses.  
Importantly, the D. melanogaster genome has been extensively studied, and it was completely 
sequenced in 2000 [11,12]. It encompasses ~143 Mbp, organised into four pairs of chromosomes—
two X/Y sex chromosomes and three autosomes. The genome contains ~16,000 genes, of which 
~13,000 code for proteins. Among the protein-coding genes, more than 60% have an orthologous 
counterpart in humans, representing promising candidates for translational studies [13]. In addition, 
for some cases in which human genes do not show an obvious fly homologue, fly–human 
conservation might still occur at the level of the pathway in which these factors are involved, making 
Drosophila-based studies again informative [13]. In the next section, we briefly describe the most 
common genetic tools used in fly studies. 
2.1. Generation and Maintenance of Mutant Fly Lines  
Both forward and reverse genetic studies are based on the availability of mutant gene variants. 
Over the last century, several strategies and tools have been developed to obtain multiple collections 
of lines in D. melanogaster, characterised by different types of mutations. Mutant alleles are initially 
obtained using chemical (e.g., ethyl methanesulfonate, EMS) or radiation (X-ray) mutagenesis. The 
advent of the P-element-mediated transformation developed in flies by Rubin and Sprandling [14,15] 
raised the possibility of introducing any DNA sequence into the Drosophila genome, generating 
transgenic lines stably inheriting the inserted sequence. Methodologies based on fly transgenesis and 
random insertion of transposon vectors created large-scale collections of fly lines carrying mutant 
insertional alleles, including amorphic and hypomorphic variants [16,17]. Additional strategies 
exploiting homologous recombination (HR) [18] or the induction of double-strand breaks followed 
by HR, or error-prone nonhomologous end-joining such as TALENs and ZNFs [19,20], were 
established to target and modify specific genes. The possibility to mutate specific genes into the fly 
genome has been improved with the introduction of the CRISPR/Cas9 (clustered regularly 
interspaced short palindromic repeats/ CRISPR-associated nuclease) technology in D. melanogaster. 
Several groups contributed to the development of this methodology [21–24], making available to the 
fly community protocols and tools for using this strategy to generate mutant flies [25] 
(https://flycrispr.org/; https://www.crisprflydesign.org/). Recent advancements in CRISPR/Cas9 
technology have allowed tissue-specific mutagenesis, which will permit fine dissection of the roles 
of specific genes in complex biological processes [26]. 
Independently of the strategy employed to obtain mutations, the availability of balancer 
chromosomes, peculiar chromosomes carrying multiple inversions, thereby inhibiting homologous 
recombination [27], allows the production of stock lines in which recessive lethal or sterile alleles can 
be stably maintained in heterozygosity. The use of balancer chromosomes also facilitates the 
production of fly lines carrying mutations at the level of multiple genes.  
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2.2. The GAL4/UAS System 
The possibility to manipulate gene expression and activity in a spatially and/or temporally 
controlled manner is one of the main strengths of the fly model. Common tools used for these 
analyses are based on the GAL4/UAS system originally developed by Brand and Perrimon [28]. In 
principle, this system relies on the generation of two different types of parental transgenic lines. The 
first parental line carries a construct in which a specific fly cis-regulatory sequence (enhancer and/or 
promoter region) promotes the expression of the coding region of the yeast transcription factor GAL4 
(GAL4-driver). The second line carries a transgene in which DNA of interest is cloned under the 
control of the upstream activating sequences (UAS) specifically recognised by GAL4. In the progeny 
derived from the cross between the two parental lines, the UAS-controlled DNA sequence will be 
actively transcribed only in those tissues where GAL4 is expressed, allowing the analysis of its effect 
in a spatially-controlled way [28]. Moreover, GAL4 expression can be temporally regulated by 
adding to the system a third transgene specifying a temperature-sensitive transcription factor, 
GAL80ts. Indeed, GAL80ts can bind to GAL4, repressing its transcriptional activity at the permissive 
temperature of 18 °C, while its inhibitory function is removed at higher temperatures, allowing GAL4 
binding to UAS [29]. A recent refinement of the technique includes the split GAL4, which improves 
the temporal control of gene expression. In this system, the transcriptional activation domain of 
GAL4 and its DNA-binding domain are cloned in separated promoters. Hence, only when the two 
domains bind to each other is GAL4 reconstituted and functional [30].  
The number of GAL4 and GAL80ts lines has increased over time, allowing multiple and versatile 
combinations. Similarly, many transgenic UAS lines have been produced. Depending on the nature 
of the UAS construct, these lines can be used to study the effects of ectopic expression of a specific 
gene product, including those not present in the fly genome, or to explore the consequence of a gene’s 
downregulation via RNA interference.  
Other GAL4/UAS-based tools available for Drosophila are the EP lines. Each of these lines carries 
a randomly inserted EP element, a P transposon containing UAS sites. When activated using a GAL4-
driver, the EP-element can induce mis-expression of endogenous genes located at the site of insertion. 
Such mis-expression can have phenotypic consequences, the characterisation of which allows the 
identification of novel genes or for new roles to be ascribed known genes. Thousands of EP lines have 
been produced and are available for screening studies [17,31–33].  
2.3. Other Tools to Monitor Gene Expression in D. melanogaster 
Different tools have been also developed to perform expression studies of fly proteins without 
the need for specific antibodies, which are often challenging to obtain for Drosophila. An early tool 
was based on the generation of transgenic lines carrying a randomly inserted green fluorescent 
protein (GFP)-coding artificial exon [34]. Subsequently, other methodologies, such as “MiMIC” 
(Minos-mediated integration cassette) [35] and “CRIMIC” (CRISPR mediated integration cassette) 
[36], based on the use of exchangeable ϕ-C3 integrase cassettes, were developed. In addition, 
strategies relying on the production of genomic P[acman] BACs or fosmids modified to tag protein-
coding regions are also available [37–39]. These approaches allow characterisation of the expression 
of endogenous proteins at the tissue, cellular and subcellular levels as well as immunoprecipitation 
and live-imaging experiments, as reviewed in Reference [33]. Importantly, several lines for protein 
tagging studies are now available from public repositories.  
3. D. melanogaster as a Model to Investigate PD Pathology 
The fly central nervous system is a bilaterally symmetrical brain composed of both neurons and 
glial cells. Notwithstanding its simplicity, the Drosophila brain coordinates complex behaviours such 
as circadian rhythms, sleep, memory, locomotion and learning. Moreover, D. melanogaster has been 
found to respond to drugs acting on the central nervous system similarly to mammals [40–42]. The 
fruit fly brain includes a well-characterised set of dopaminergic (DA) cells. DA neurons are 
subdivided into multiple clusters, which are symmetrically distributed and easily recognisable in the 
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fly brain [43,44]. Similarly to mammals, the DA system is involved in the control of locomotion and 
other complex behaviours, including olfaction, memory, learning and sleep [45]. This remarkable 
degree of conservation, combined with the possibility of exposing flies to PD-linked toxins, has led 
to the investigation of PD-related phenotypes including DA neurodegeneration and dysfunctional 
locomotion. DA neuronal loss is normally evaluated by counting the number of neurons positive to 
tyrosine hydroxylase (TH) immunostaining, the rate-limiting enzyme in dopamine synthesis [44]. 
Locomotor alterations are usually evaluated by measuring startle-induced negative geotaxis, a 
typical Drosophila behaviour, also known as climbing. Once inside the experimental tubes, flies 
display the spontaneous tendency to climb following a slight stimulus [46]. Besides the availability 
of these tools, one great advantage of using D. melanogaster in the study of PD derives from the 
conservation of many PD-related genes. In fact, parkin, Pink1, LRRK2 and dj-1 mutant strains have 
been generated to investigate the mechanisms leading to the disease. Interestingly, parkin and Pink1 
mutants are characterised by reduced lifespan, mitochondrial pathology, apoptotic muscle 
degeneration and DA neuron degeneration [47,48]. Differently, dj-1 loss of function confers milder 
phenotypes [49,50], which emerges particularly under oxidative treatments. Regarding dominant 
loci, LRRK2-null animals have been shown to present inconsistent phenotypes. Indeed, according to 
some reports, deficient flies show DA cell loss and locomotor deficits [51], while other studies did 
not find evidence of degeneration [52]. Interestingly, the expression of human LRRK2 or the 
Drosophila homologue confers age-dependent DA cell death and locomotor alterations [53–55]. In 
contrast to the other PD genes, the fly genome does not bear an α-synuclein encoding gene. Hence, α-
synuclein fly models are uniquely based on the ectopic expression of the human gene, both in mutated 
and wild-type form. Interestingly, transgenic flies overexpressing the protein develop LB-like 
inclusions, DA neuron degeneration and locomotor defects [56]. Furthermore, Drosophila shares high 
homology with the mammalian innate immune response of the brain, allowing the investigation of 
the PD-related neuroinflammatory mechanisms [57]. Therefore, considering these findings, the fruit 
fly represents a valuable system to model PD-linked genes and to dissect the related mechanisms of 
neurodegeneration.  
4. Drosophila as a Model to Evaluate In Vivo Redox Alterations  
Besides the conservation of several PD genes and the availability of behavioural tools, the 
potentiality of Drosophila as a PD model is further supported by the possibility of investigating in 
vivo the role played by oxidative stress in the neurodegenerative process. To date, several transgenic 
flies carrying redox-sensitive probes have been generated [58,59]. The existing sensors rely on redox-
sensitive green fluorescent protein constructs (roGFP), which enable the exploration of cellular 
changes in the redox state mainly by exploiting glutathione oxidation (roGFP-Grx1, where roGFP is 
fused to glutaredoxin 1) or H2O2 concentration (roGFP-Orp1, where roGFP is linked to the H2O2-
specific peroxidase Orp1) as readout [60]. Moreover, thank to further refinements, these probes can 
now be specifically expressed in different subcellular compartments, such as the cytosol or 
mitochondria, markedly improving the spatial resolution [59,61]. Transgenic fly lines harbouring 
these advanced sensors have been already used to explore the in vivo redox changes occurring in 
normal physiology and in pathological states [59,61]. For example, the use of the mitochondrially 
targeted H2O2-sensitive probes has shown that this ROS species is increased in both Pink1 and parkin 
mutants, supporting the existence of a dysregulated redox homeostasis in these PD models [62]. 
Therefore, the availability of fly lines carrying redox-sensitive probes could significantly contribute 
to elucidation of the complex role played by the redox homeostasis in such pathological conditions. 
In addition to these useful tools, fruit flies have also been exploited to screen antioxidant 
compounds with therapeutic potential in neurodegenerative diseases. These molecules can be easily 
administered through the flies’ food and their effects evaluated over time through behavioural and 
biochemical analysis [63]. Ingestion can be actively monitored by adding inert coloured compounds 
to the standard fly food in which the molecule of interest is dissolved, or, alternatively, the compound 
solution can be directly injected into the fly abdomen to ensure complete absorption [63]. In this way, 
Drosophila can substitute for in vitro approaches, overcoming the limitations associated with cell-
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culture-based high-throughput screenings, which cannot mimic the whole-tissue response. Indeed, 
despite the introduction of 3D cultures, the results obtained with in vitro approaches cannot be 
generalised in vivo [64]. Drosophila represents a suitable in vivo model with which to perform 
preliminary drug screening studies to identify new candidate compounds [65,66], while also 
allowing the investigation of potential side effects, for instance by evaluating the mortality rate, 
embryonic development, adult morphology and behavioural traits [67,68]. Nonetheless, as drug 
response profiles can differ between fruit flies and humans due to the evolutionary distance, 
Drosophila should be considered as a preliminary drug discovery platform, the results of which 
should be further validated in higher model organisms to clarify their translational relevance. The 
major advantages of D. melanogaster as a model to study PD are summarised in Figure 2. 
 
Figure 2. Advantages of Drosophila melanogaster as a model organism to investigate PD. D. 
melanogaster offers numerous advantages as a model organism for the study of PD-related features. 
(A) Fruit flies share many of the human genes involved in PD, allowing the generation of PD-mutant 
organisms which can then be investigated through different approaches; (B) longevity; (C) evaluation 
of dopaminergic (DA) cell loss; (D) locomotor defects, e.g., evaluated by climbing; (E) response to 
PD-toxins and therapeutic compounds and (F) ROS levels. The picture in (C) was produced in our 
laboratory by generating flies that overexpress GFP in DA neurons via TH-GAL4 driver. The picture 
in (F) was adapted from Reference [62]. 
5. Drosophila as a Model to Probe Antioxidant Therapies in PD: Insights from α-synuclein, 
parkin/Pink1 and dj-1 PD Models 
In this section, we describe the use of Drosophila PD models that have mainly contributed to 
investigation of potential antioxidant drugs in the disease. Among the genetic models available, the 
ones that are mainly utilised are based on the heterologous expression of human α-synuclein or on 
the loss of function or downregulation of the fly homologues of Parkin, PINK1 and DJ-1. Indeed, these 
fly lines are characterised by altered redox homeostasis, thus representing an appropriate model to 
evaluate antioxidant compounds. As summarised in Table 1, for each gene, we have provided a brief 
introduction followed by a description of its characterisation in D. melanogaster and the associated 
antioxidant-based studies. 
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Table 1. Antioxidant treatments positively evaluated in Drosophila genetic PD models. 
Fly PD Model Associated PD Phenotypes Antioxidant Molecules/Pathways Tested 
α-synuclein 
(overexpression of the 
human homologue) 
LB-like inclusions, DA 
degeneration, climbing defects 
[56], lipid peroxidation and 
protein carbonylation [69,70] 
• GstS1 upregulation [71] and overexpression 
of bovine MSRA [72] or human SOD1 [73] 
• S-methyl-L-cysteine[7 2], curcumin [74], 
epicatechin gallate [75], grape extract [76], 
Decalepis hamiltonii [70], Eucalyptus citriodora 
[77] and Centella asiatica [69] 
parkin 
(Loss of function) 
DA degeneration [78–81], 
climbing defects [79,81,82], 
mitochondrial dysfunctions 
[79,80,83] and sensitivity to 
oxidative treatments [83] 
• GstS1 upregulation [81] and overexpression 
of fly Sod1 and Sod2 [62] 
• polyphenols (propyl gallate and 
epigallocatechin gallate) [84] 
• M40403 (SOD-mimetic) [62] 
pink1 
(Loss of function) 
DA degeneration [47,79], 
climbing defects [47,79], 
mitochondrial dysfunctions 
[47,79,85] and sensitivity to 
oxidative treatments [85] 
• overexpression of human SOD1 [86] and of 
fly Sod1 and Sod2 [62] 
• M40403 (SOD-mimetic) [62] 
dj-1α and dj-1β 
(Loss of function, 
single and double 
mutants) 
Sensitivity to oxidative 
treatments [49,50], lipid 
peroxidation and protein 
carbonylation [87,88] 
• minocycline and celastrol [89] 
• vitamin C and vitamin E [87,88], Spirulina 
[90], epigallocatechin-3-gallate [91], 
pterostilbene, methylene blue, 
dalfampridine, sodium phenylbutyrate and 
dexrazoxane [65] 
DA: dopaminergic neurons; GstS1: glutathione-S-transferase S1; LBs: Lewy bodies; MSRA: 
methionine sulfoxide reductase A; SOD1: superoxide dismutase 1. 
5.1. α-synuclein Models 
α-Synuclein is a small protein (14 kDa) particularly enriched at presynaptic terminals [92]. The 
protein is normally found in a dynamic equilibrium between a soluble cytosolic state and a 
membrane-bound state [92]. While in the former, the protein is unstructured, in the latter state, α-
synuclein assumes an α-helix conformation. In its membrane-bound form, it seems to participate in 
neurotransmitter release and vesicle recycling, although the physiological function is still elusive 
[92]. Even though fruit flies lack a homologous gene, α-synuclein-overexpressing lines have been 
produced to investigate the physiopathological function of the protein. However, while the absence 
of a fly homologue allows specific investigation of the role of α-synuclein without any interference 
from an endogenous counterpart, in particular when pathological mutations are inserted in its 
sequence, the observed phenotypes could, on the other hand, represent a nonspecific consequence of 
foreign protein expression that cannot be properly managed by the organism. The overexpression of 
human α-synuclein and its A30P or A53T mutants does not affect the development of neuronal and 
non-neuronal tissues, nor does aging produce any gross, widespread degenerative changes [56]. 
However, flies expressing wild-type and mutant forms of the protein are characterised by a specific 
loss of dopaminergic neurons and by the appearance of α-synuclein aggregates that strongly 
resemble cortical LBs from patients with diffuse LB disease [56]. Together with these pathological 
phenotypes, the locomotion behaviour of α-synuclein transgenic flies has been demonstrated to 
decline more rapidly during aging than control flies, with a time course of climbing dysfunction that 
parallels the degeneration of dopaminergic neurons and the appearance of α-synuclein inclusions 
[56]. More recently, increased levels of ROS and cellular markers of oxidative damage such as lipid 
peroxidation and protein carbonylation have been measured in α-synuclein-expressing flies [69,70]. 
The presence of PD-related phenotypes in the α-synuclein-overexpressing flies has been used 
as a readout to test the protective effects mediated by endogenous detoxification pathways or by 
exogenous molecules. For instance, an impairment in glutathione metabolism has been shown to 
enhance the loss of dopaminergic neurons, whereas the overexpression of factors involved in 
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glutathione biosynthesis and conjugation has been observed to suppress α-synuclein toxicity [71]. 
Interestingly, similar protective effects were also observed when feeding flies with sulphorafane and 
allyl disulfide, which have been demonstrated to significantly increase glutathione abundance [71]. 
In light of the known role of glutathione in protecting from oxidative stress, these data associate α-
synuclein toxicity with oxidative damage. Accordingly, the overexpression of the enzyme 
methionine sulfoxide reductase A, which has been postulated to function as a catalytic antioxidant 
mechanism [72], has been demonstrated to markedly slow down the climbing deficits induced by 
wild-type or A30P α-synuclein and to preserve dopaminergic neurons from age-related degeneration 
[72]. In addition, statistically significant protection was observed when flies were fed with the non-
toxic methionine analogue S-methyl-L-cysteine, which is a substrate of methionine sulfoxide 
reductase A [72]. Further experimental evidence on the involvement of oxidative damage in α-
synuclein toxicity has arisen from a third study, in which both locomotion impairment and neuronal 
degeneration were reduced by the overexpression of superoxide dismutase 1 (SOD1), an antioxidant 
enzyme that participates in the removal of superoxide radicals [73]. In addition to the 
aforementioned studies aimed at evaluating how the activation of endogenous antioxidant pathways 
could be protective in the α-synuclein-based fly model of PD, more recent analyses have focused on 
the effects exerted by different natural antioxidant molecules, such as curcumin, epicatechin gallate, 
grape extracts, Decalepis hamiltonii root extracts and Eucalyptus citriodora and Centella asiatica leaf 
extracts [69,70,74–77]. Notably, every antioxidant molecule tested showed protective effects. 
5.2. parkin and Pink1 Models 
As previously mentioned, Parkin and PINK1 collaborate to drive the disposal of old or damaged 
mitochondria through a process called mitophagy [93]. Interestingly, studies carried out in Drosophila 
models first emphasised the role of both proteins in mitochondrial homeostasis [47,82,85]. When 
mitochondria are damaged, Pink1 is stabilised on the mitochondrial outer membrane, where it 
recruits and phosphorylates parkin, inducing its E3 ligase activity, which labels mitochondria for 
degradation [93]. The phenotypes associated with the deletion of these genes have been largely 
characterised in Drosophila models, and most of them recapitulate the phenotypes observed in PD 
patients. Specifically, parkin-null mutants show a reduced life span and impaired locomotion 
activities [78,80,82,83]. Moreover, the degeneration of dopaminergic neurons has also been described, 
as well as mitochondrial defects [78,81]. The phenotypes associated with Pink1 deficiency are almost 
identical to those observed in parkin Drosophila mutants [47,79,85]. Besides mitochondria alterations, 
Pink1- or parkin-null mutants have also been described to be associated with increased susceptibility 
to oxidative conditions. More specifically, Pink1-deficient flies show increased sensitivity to oxidative 
insults [85], while parkin mutant flies are characterised by an alteration in oxidative stress response 
[94] and enhanced sensitivity to oxygen radical injury [83]. More recently, through the use of redox-
sensitive probes that specifically accumulate either at the cytosolic or mitochondrial level, we 
observed increased mitochondrial ROS in parkin- and Pink1-null mutants, while no significant 
changes in cytosolic ROS were detected [62]. 
The enhanced susceptibility to oxidative conditions has been the rationale for the analysis of the 
potential protective effects mediated by antioxidant molecules in Pink1 and parkin Drosophila models 
of PD. First, as in the case of the α-synuclein model, alterations in glutathione metabolism have been 
shown to increase the neurodegenerative phenotypes of parkin mutants, while the overexpression of 
glutathione S-transferase S1 prevented dopaminergic neuron degeneration [81]. In another study 
performed in a knockdown parkin model, the pre-incubation of flies with a low concentration of 
paraquat (PQ) (0.1 mM) was shown to be able to prolong life-span and improve locomotion activity 
[84]. As PQ is a pesticide known to increase the production of superoxide radicals [95], these 
protective effects observed have been suggested to derive from an adaptive stress response referred 
to as “hormesis” [96]. In the same experimental model, when polyphenols such as propyl gallate or 
epigallocatechin gallate were added to low concentrations of PQ, a synergistic protective effect was 
observed. The antioxidant activity of those polyphenols was, however, unable to protect flies in the 
presence of higher PQ concentrations (>0.25 mM) [84]. In another study performed on a Pink1 
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knockdown model, the expression of the human antioxidant enzyme SOD1 was shown to prevent 
the degeneration of dopaminergic neurons, confirming that the loss of Pink1 is associated with 
increased oxidative conditions that can eventually lead to neuronal degeneration [86]. In light of the 
mitochondrial localisation of Pink1, and considering that mitochondria are the main endogenous 
source of ROS, PD-associated Pink1 mutations might disrupt mitochondrial homeostasis, resulting 
in the production of radical species. 
5.3. dj-1 Models 
DJ-1 has been described as a multitasking protein principally localised in the cytoplasm [97]. 
Although its physiological function remains partially elusive, the protein has been suggested to 
participate in maintenance of the cellular redox state by regulation of the antioxidant defence [98]. 
Multiple pieces of evidence have shown that the absence of DJ-1 results in impaired redox 
homeostasis, characterised by high levels of ROS [99]. Differently from humans, the Drosophila 
genome encodes two DJ-1 homologues, referred to as dj-1α and dj-1β. While the expression of the 
protein dj-1α is restricted to the male testes, with a minor expression in the brain, dj-1β is 
ubiquitously distributed, similarly to the human protein. Double knockout flies are viable and fertile, 
though showing a higher sensitivity to oxidative insults [49,50]. Both factors have been shown to 
exert a protective function; however, dj-1β has been demonstrated to be primarily involved in the 
antioxidant protection due to its higher expression level and its ubiquitous pattern, which resembles 
the human protein [49]. In agreement with the proposed antioxidant role of dj-1, higher levels of ROS 
and oxidative stress markers, such as protein carbonylation and lipid peroxidation, have been 
frequently observed in dj-1-deficient flies [87,88,100]. 
The sensitivity to oxidative stimuli of dj-1-deficient flies has been widely exploited in many 
studies, mostly utilising dj-1β null individuals as a platform for screening numerous antioxidants of 
both synthetic and natural origin. Among the natural molecules, the micronutrients vitamin C and 
vitamin E have been frequently used as antioxidants for their ability to buffer ROS and attenuate 
lipid peroxidation [101,102]. In this regard, a study conducted in dj-1β fly mutants demonstrated that 
the chronic administration of either vitamin C or vitamin E reduced protein carbonylation [88]. The 
same molecules were also assessed by another study for their ability to improve the longevity of dj-
1β-null flies as compared to controls [87]. Interestingly, while vitamin C showed positive effects on 
both genotypes, vitamin E showed a pro-longevity effect only on the mutant line [87]. As dj-1β-null 
flies displayed higher levels of lipid peroxidation, the authors suggested that a vitamin-E-
supplemented diet might be protective for the maintenance of membrane integrity in the absence of 
dj-1β [87]. Among the natural compounds, food supplementation with the cyanobacteria Spirulina, 
known for its antioxidant properties [103,104], has been shown to improve locomotion and survival 
rate of dj-1β-null flies under PQ exposure [90]. Moreover, epigallocatechin-3-gallate, a 
polyhydroxyphenol extracted from green tea [105], has been recently reported to positively affect the 
locomotor ability and survival rate of dj-1β knockout flies exposed to PQ [91]. Another natural 
molecule called Celastrol, derived from the root of a Chinese plant [89,106], has been described to 
rescue the dopaminergic neuronal loss and the dopamine content in flies silenced for the dj-1α 
homologue [89]. The same authors reported a similar protective activity for the semisynthetic 
tetracycline-derived antibiotic minocycline [89], which is emerging for its antioxidant and anti-
inflammatory properties [107]. 
More recently, in an attempt to identify new drugs for PD treatment, Sanz and co-workers 
conducted a broad-spectrum drug screening study in dj-1β-null flies. Promising compounds were 
been selected according to the positive effect shown on climbing ability and on the levels of ROS and 
protein carbonylation of the mutant flies [65]. Besides the previously mentioned molecules, including 
minocycline and vitamin E, the authors also examined other candidate compounds, including 
pterostilbene, an extract of blueberries [108], methylene blue, a mitochondrial targeting antioxidant 
[109], dalfampridine, a potassium channel blocker used in multiple sclerosis treatment [110], sodium 
phenylbutyrate, a histone deacetylase inhibitor with multiple medical applications [111] and 
dexrazoxane, a cardioprotective drug [112]. Interestingly, all the aforementioned compounds have 
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been shown to have antioxidative and protective properties [65]. As most of them have already been 
used in different medical applications, they appear to be promising candidates for further validation 
in antioxidant PD therapy. 
6. Superoxide Radical Dismutation as a New Therapeutic Strategy in PD 
As strongly emphasised in the previous sections, the notion that oxidative damage contributes 
to the neuronal degeneration observed in PD is commonly accepted today. However, in spite of the 
positive results obtained in many animal models of the disease, clinical trials aimed at evaluating the 
therapeutic potential of antioxidant drugs have been rather disappointing with mixed results, as 
extensively reviewed elsewhere [113]. Several reasons could account for the modest clinical 
outcomes, and a central issue seems related to the real nature of the radical species underlying the 
neuronal damage [5]. In other words, most of the tested antioxidant molecules targeted not the 
primary cause of the oxidative damage, but rather the downstream effects. Considering that 
mitochondria are the principal source of ROS and that superoxide anions are the primary radical 
species produced during the mitochondrial oxidative phosphorylation, it follows that a treatment 
strategy for oxidative stress that targets superoxide radicals could be more effective. Based on this 
rationale, we recently assessed the beneficial effects of antioxidant molecules capable of removing 
superoxide radicals in both sporadic and genetic fly models of PD [62,114]. 
As a proof of concept, we first tested the action of the endogenous superoxide dismutase 
enzymes SOD1 and SOD2 in flies treated with PQ or lacking either Pink1 or parkin proteins. Both 
SOD1 and SOD2 were protective in our models, although with different effectiveness. More 
specifically, SOD1 exerted an elevated protective action in the presence of chronic PQ treatment, even 
when the protein was specifically overexpressed in dopaminergic neurons, but was ineffective with 
higher (acute) concentrations of PQ. In contrast, the protective effects of SOD2 were more evident in 
the presence of acute treatment [114]. The overexpression of SOD2, and to a lesser extent SOD1, was 
also able to ameliorate locomotion defects in Pink1- and parkin-null mutants [62]. Given the protective 
effects observed with both SOD1 and SOD2, in an important extension to the genetic manipulation 
of superoxide dismutation, we then explored the beneficial activity of the SOD-mimetic drug 
M40403. The choice of this molecule arose from its physicochemical properties and from the fact that 
it has already been evaluated in phase I and II clinical trials for the treatment of pain, which have 
indicated that it is safe and well-tolerated [115]. M40403 is a stable Mn(II) complex which is excreted 
intact with no detectable dissociation when intravenously injected in rats [116]. Moreover, the 
molecule is water-soluble and it is able to cross the blood–brain barrier, a mandatory property for a 
drug to be effective in PD [116]. Another important feature of M40403 is its ability to dismutate 
superoxide anions in a catalytic way, with a catalytic rate comparable to that of native SOD2 
enzymatic activity or an order of magnitude lower, depending on the pH of the solution [116]. When 
tested in our PQ-based Drosophila models, M40403 was able to rescue the lethality induced by 
elevated concentrations of PQ and improve the locomotion behaviours of flies treated with sub-lethal 
concentrations of PQ [114]. Beneficial effects were also observed from the systemic administration of 
M40403 in both Pink1- and parkin-null mutants, even though the dose–response effects were slightly 
different between the two fly models [62]. Overall, our results indicate that the selective removal of 
superoxide anions could represent a new and more effective approach to cope with the enhanced 
oxidative conditions associated with PD, and support the further exploration of exogenous SOD-
related molecules as a therapeutic strategy against PD. 
7. Conclusions 
PD is a complex disorder in which genetic susceptibilities and environmental factors participate 
in the pathogenesis of the disease. The multifactorial origin and the numerous cellular pathways 
affected by the disorder make it difficult to define a therapeutic strategy able to hamper its 
progression, and the current pharmacological approach is mostly aimed at replacing the action of 
dopamine at the striatal level. The pathogenesis of PD has been largely studied in the last years and, 
even though it is still partially elusive, many factors have been clarified. Among them, the roles of 
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mitochondrial dysfunction and oxidative damage have been clearly demonstrated and are 
commonly accepted. This aspect has supported testing of the protective actions of numerous natural 
or synthetic antioxidant molecules in different animal models of the disease. While every single 
model presents some of the phenotypes associated with the disease, none is able to reproduce every 
clinical and pathological feature of PD. This is most likely one of the reasons why the results observed 
in animal models are almost never reproduced in clinical trials. Among the different animal models 
available to test the protective action of antioxidant molecules, D. melanogaster presents several 
advantages. The rapid reproductive cycle, short lifespan, powerful genetic tools and exemption from 
restrictive animal monitoring regulations allow for the rapid exploration of the proposed hypotheses 
in vivo on a statistically powerful number of individuals. Moreover, the genome encodes 
homologues for most of the currently identified PD genes [117], making it possible to easily evaluate 
a purported drug in different models of the disorder. One of the key aspects to be considered in the 
definition of successful antioxidant-based therapies is the nature of the oxidative species involved in 
the pathology. Given that the accumulation of dysfunctional mitochondria, which inevitably produce 
high levels of superoxide anions, is a key pathological factor associated with PD, it follows that 
molecules specifically directed against this radical species should be more effective in comparison to 
compounds that target the downstream effects of superoxide radical accumulation. While further 
work is required for a better understanding of the detrimental effects induced by the accumulation 
of superoxide radicals on the neuronal viability, the exploration of exogenous SOD-mimetic 
molecules as a therapeutic strategy against PD appears rather promising. 
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